[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 637
Citations 0
Comment & Response
October 2015

Temporal Artery Biopsy in Giant Cell Arteritis

Author Affiliations
  • 1Department of Ophthalmology, Jozef Strus Poznań City Hospital, Poznań, Poland
  • 2Department of Ophthalmology, University of Warmia and Mazury, Olsztyn, Poland
  • 3Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston
  • 4Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston
  • 5Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
JAMA Ophthalmol. 2015;133(10):1220. doi:10.1001/jamaophthalmol.2015.2552

To the Editor We read with interest the study by De Lott et al,1 but we believe that further discussion is justified. It should be emphasized that the diagnosis of giant cell arteritis (GCA) is based on the combination of clinical picture, laboratory test results (C-reactive protein level [CRP], erythrocyte sedimentation rate [ESR], and platelet count), and histopathological findings.2 Because treatment with corticosteroids must be started as soon as the diagnosis is suspected, temporal artery biopsy (TAB) is usually performed at or after the induction of therapy. In many cases, a positive biopsy result is helpful not just to confirm the diagnosis made on the basis of clinical picture and laboratory tests but also to justify long-term steroid use in patients with a high chance of immunosuppressive-related morbidity. Limiting the evaluation of patients with GCA to clinical and laboratory parameters, even those applied to a statistical model, may result in false-negative results and/or undertreatment of a potentially blinding disease.

First Page Preview View Large
First page PDF preview
First page PDF preview
×